The company's stock has gained significant momentum, rising over 10% in the last 90 days and 4.3% this week alone. Recent performance is driven by record revenues, rising profit margins, and stronger financial guidance. Analysts highlight the company's sharper valuation edge compared to peers in the retail pharmacy and healthcare benefits sector. While the consensus price target saw a minor downward adjustment, the overall outlook remains positive due to growing confidence in the company's execution and its cheaper valuation relative to competitors.